CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤的嵌合抗原受体（CAR）T 细胞治疗
英文原题：Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
查看英文原题
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对T细胞进行基因修饰以表达嵌合抗原受体（CAR），已带来显著临床疗效，并开启癌症免疫治疗新时代。血液系统恶性肿瘤中令人瞩目的临床应答推动了CAR-T 细胞在实体瘤中的研究，但迄今取得类似疗效仍十分困难。胶质母细胞瘤（GBM）尤其难以治疗；尽管过去十年治疗有所进步，多数患者预后仍较差。不过，近期数据支持CAR-T 细胞治疗GBM具有临床疗效和安全性。本综述讨论GBM治疗中常见的挑战及CAR-T 细胞克服这些障碍的方式，并重点介绍优化GBM CAR-T 治疗的新兴技术，展望细胞免疫疗法的应用潜力。
展开英文摘要原文
Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies have led to the investigation of CAR T cells in solid tumors but attaining similar results has been challenging to date. Glioblastoma (GBM) presents a particularly challenging malignancy for treatment and despite some progress in treatments over the past decade, prognosis remains poor for the vast majority of patients.
However, recent data support the clinical efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers.
Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.
论文信息
- 作者
- Verma A、Rafiq S
- 第一作者单位
- Winship Summer Scholars Research Program, Emory University, Atlanta, GA, USA.United States
- 通讯作者单位
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. Sarwish.Rafiq@emory.edu.United States
- 文献类型
- 综述
- 期刊
- Cancer treatment and research2022
- 原文标识
- PubMed 35551659 · DOI 10.1007/978-3-030-96376-7_5